Acasti Pharma Inc. (ACST) 10-Q Quarterly Report February 2022

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Dec. 31, 2021	Feb. 14, 2022
Cover [Abstract]
Entity Central Index Key	0001444192
Entity Registrant Name	Acasti Pharma Inc.
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	001-35776
Entity Incorporation, State or Country Code	Z4
Entity Tax Identification Number	98-1359336
Entity Address, Address Line One	3009 boul. de la Concorde East, Suite 102
Entity Address, City or Town	Laval
Entity Address, State or Province	QC
Entity Address, Country	CA
Entity Address, Postal Zip Code	H7E 2B5
City Area Code	450
Local Phone Number	686-4555
Title of 12(b) Security	Common Shares, no par value per share
Trading Symbol	ACST
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		44,288,183

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1444192/000095017022001147/acst-20211231.htm

View differences made from one quarter to another to evaluate Acasti Pharma Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Acasti Pharma Inc..

Continue

Assess how Acasti Pharma Inc.'s management team is paid from their Annual Proxy

Acasti Pharma Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Financial

Revenue

Legal

M & A

Other

Filter Subcategory:

All

Expense

Product

Geography

Cash Flow

Other

Inside Acasti Pharma Inc.'s 10-Q Quarterly Report:

Financial - Shares Highlight
Issued and outstanding fully paid shares, stock options, and warrants, were as follows for the periods ended (after giving effect to our 8:1 share consolidation, which became effective on August 31, 2021): Cash Flows and Financial Condition between the Three and Nine-Months ended December 31, 2021, and 2020 Summary As at December 31, 2021, cash and cash equivalents totaled $33,013 a net increase of $6,467 compared to cash and cash equivalents totaling $26,546 at December 31, 2020.

Financial - Expense Highlight
Depreciation and amortization expense decreased by $142 for the nine months ended December 31, 2021, to nil as compared to $142 for the nine months ended December 31, 2020.
Revenue - Product Highlight
Assets Held for Sale We determined to actively market for sale Other assets and Equipment and have met the criteria for classification of assets held for sale: Other assets Other assets represent krill oil (RKO) held by us that was expected to be used in commercial inventory scale up related to the development and commercialization of the CaPre drug candidate.
Legal - Other Highlight
This increase was a result of increased legal, tax, accounting and other professional fees of $220 related to legal, accounting and other professional fees connected to the filing of a prospectus supplement for our renewal of our at-the-market program, on November 10, 2021.
Financial - Expense Highlight
Stock-based compensation expense decreased by $282 for the nine months ended December 31, 2021, amount to $721, as compared to $1,003 for the nine months ended December 31, 2020.
Revenue - Product
Under the terms of the...Read more
Revenue - Product
Under the terms of the...Read more
Financial - Expense
In June 2016, the Financial...Read more
Financial - Expense
The decrease in expense was...Read more
Revenue - Product
Under the terms of the...Read more
Other - Other
We strive to protect and...Read more
Financial - Expense
The increase in net loss...Read more
M & A - Other
The following tables summarizes the...Read more
M & A - Other
Acquired In-Process Research and Development...Read more
Other - Other
The increase in cash generated...Read more
Other - Other
The increase in cash generated...Read more
Other - Other
This unique nimodipine injectable formulation...Read more
Other - Other
These drug candidates aim to...Read more
Financial - Expense
R&D expenses decreased by $487...Read more
Other - Other
More consistent dosing is expected...Read more
Financial - Expense
The allowance for credit losses...Read more
Revenue - Geography
The duration of foreign patents...Read more
Revenue - Geography
We have credit risk relating...Read more
Financial - Expense
For assets held at amortized...Read more
Other - Other
In addition, there was a...Read more
Financial - Expense
General and administrative expenses totaled...Read more
Financial - Expense
General and administrative expenses totaled...Read more
M & A - Other
Finalization of the valuation during...Read more
Financial - Cash Flow
If the carrying amount is...Read more
Other - Other
Generally, utility patents issued for...Read more
Financial - Cash Flow
Interest Rate Risk Interest rate...Read more
Legal - Other
This increase was a result...Read more
Other - Other
b.Median differences between the change...Read more
M & A - Other
This acquisition method requires, among...Read more
Other - Other
An impairment of indefinite-lived intangible...Read more
Revenue - Product
Measurement of Assets Held for...Read more
Other - Other
Cash equivalents and marketable securities...Read more
Financial - Expense
Total costs incurred to register...Read more
Revenue - Geography
Derivative Warrant Liabilities A total...Read more
Other - Other
Any impairment loss to be...Read more
Revenue - Geography
We also rely on trade...Read more
Other - Other
Similar to the intangible assets...Read more
Other - Other
ASU 2016-13 is effective for...Read more
Financial - Expense
General and administrative expenses also...Read more
M & A - Other
In addition, salaries and benefits...Read more
M & A - Other
In addition, salaries and benefits...Read more
Financial - Expense
Costs incurred relating to prospectus...Read more
Other - Other
The December 2017 warrants are...Read more
Other - Other
Our patent estate includes more...Read more
Other - Other
Assuming in the worst case...Read more
M & A - Other
The net increase was mainly...Read more
Other - Other
Therefore, GTX-104 could be considered...Read more
M & A - Other
Acquisition-related expenses, which were comprised...Read more
Other - Other
There were no serious adverse...Read more
Other - Other
There were no serious adverse...Read more
Revenue - Geography
On November 10, 2021, we...Read more
Other - Other
Liquidity Risk Liquidity risk is...Read more
Other - Other
Furthermore, a portion of our...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Acasti Pharma Inc. provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: ACST
CIK: 1444192
Form Type: 10-Q Quarterly Report
Accession Number: 0000950170-22-001147
Submitted to the SEC: Mon Feb 14 2022 6:30:40 AM EST
Accepted by the SEC: Mon Feb 14 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations